Homepage23E2 • FRA
add
Ekso Bionics Holdings Inc
Vorige slotkoers
€ 0,41
Dag-range
€ 0,37 - € 0,37
Jaar-range
€ 0,37 - € 1,86
Beurswaarde
8,84 mln. USD
Gem. volume
36,00
Koers/winst
-
Dividendrendement
-
Primaire beurs
NASDAQ
In het nieuws
EKSO
8,06%
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
(USD) | sep 2024info | Wijziging j-o-j |
---|---|---|
Opbrengst | 4,13 mln. | -10,38% |
Bedrijfskosten | 4,85 mln. | -10,01% |
Netto inkomsten | -2,07 mln. | 38,42% |
Netto winstmarge | -50,18 | 31,30% |
Winst per aandeel | — | — |
EBITDA | -2,23 mln. | 10,97% |
Effectief belastingtarief | — | — |
Balans
Totale activa
Totale passiva
(USD) | sep 2024info | Wijziging j-o-j |
---|---|---|
Contanten en kortetermijnbeleggingen | 8,29 mln. | -16,55% |
Totale activa | 29,21 mln. | -6,33% |
Totale passiva | 14,34 mln. | -9,96% |
Totaal aandelenvermogen | 14,87 mln. | — |
Uitstaande aandelen | 22,00 mln. | — |
Koers-boekwaardeverhouding | 0,61 | — |
Rendement op activa | -23,48% | — |
Rendement op kapitaal | -33,02% | — |
Kasstroom
Nettomutatie in liquide middelen
(USD) | sep 2024info | Wijziging j-o-j |
---|---|---|
Netto inkomsten | -2,07 mln. | 38,42% |
Operationele kasstroom | -2,28 mln. | 32,09% |
Kasstroom uit beleggingen | -8,00K | 52,94% |
Kasstroom uit financiering | 4,69 mln. | — |
Nettomutatie in liquide middelen | 2,41 mln. | 171,42% |
Vrije kasstroom | -1,11 mln. | 57,80% |
Over
Ekso Bionics Holdings Inc. is a company that develops and manufactures powered exoskeleton bionic devices that can be strapped on as wearable robots to enhance the strength, mobility, and endurance of industrial workers and people experiencing paralysis and mobility issues after a brain injury, stroke, multiple sclerosis or spinal cord injury. They enable individuals with any amount of lower extremity weakness, including those who are paralyzed, to stand up and walk.
Ekso Bionics currently focuses in the health and industrial sectors.
The company's first commercially available health product was called EksoGT. Ekso Bionics is the original developer of HULC, now under military development by Lockheed Martin, and the current developers of EksoNR, which allows patients who are relearning to walk the ability to stand and take steps. In December 2022, Ekso Bionics acquired the Human Motion & Control business unit from Parker Hannifin which includes the Indego product line. This acquisition allowed Ekso Bionics to begin selling exoskeletons to those who have an SCI and want a personal exoskeleton to walk at home and in their community. Wikipedia
CEO
Opgericht
2005
Hoofdvestiging
Website
Werknemers
70